NewsSource: EClinCloud

EClinCloud Product Overview | RTSM · Randomization and Trial Supply Management System

2 min readEClinCloud Editorial Team
Article image

Source: EClinCloud. Author: EClinCloud.

Article image



The EClinCloud RTSM (Randomization and Trial Supply Management) system is an advanced, web-based randomization and drug supply management platform built for multicenter clinical trials. Designed to efficiently manage large-scale, multicenter clinical trials running multiple protocols in parallel, it supports investigators in implementing a range of study models, including complex randomization schemes and trial designs. Through the EClinCloud platform, investigators can control trial workflows more precisely, ensure smooth trial conduct, and improve drug supply management and utilization.


RTSM

One-Stop Product + Service Solution





1

What Does EClinCloud Offer?

1

RTSM System

2

System Configuration and Management Services

3

Randomization and Blinding Services

4

Drug Supply and Management Services


2

EClinCloud RTSM System Features

1

Preconfigured with multiple randomization algorithms and blinding options to support multi-stage block designs

2

Uses an integrated treatment regimen design module to simultaneously manage multiple protocol versions and multiple treatment regimen assignments

3

Provides a comprehensive suite of granular management capabilities across the entire subject trial lifecycle

4

Provides integrated drug management with intelligent plan comparison and early-warning alerts




3

Why Choose EClinCloud RTSM?

Article image

Automated and standardized workflows enhance the authenticity and credibility of study data, providing solid support for clinical research

Clean interface and clear workflows that adapt to changing protocol requirements and improve efficiency

Closed-loop drug supply control and intelligent alerts provide a comprehensive solution for drug management in clinical trials

Highly adaptable and flexible system that seamlessly integrates with diverse systems to enable data interoperability




About EClinCloud

EClinCloud is a technology company dedicated to clinical R&D. It provides an integrated, interoperable unified clinical trial cloud platform (including technology products such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, as well as solutions within protocols such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) alongside clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system, ophthalmology, and others). Combining cutting-edge technology with life data, EClinCloud is building a globally leading "patient-centric" clinical evidence support SaaS cloud platform to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs/devices, and benefit countless patients.







Article image

Read the original WeChat article

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.